Rezetamig

雷泽妥米单抗

Report date: 2026/03/19 17:23:00

Base Information

Drug NameRezetamig

Drug Alias NameJNJ-75348780JNJ-8780JNJ75348780

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 stimulantsAnti-CD22

TargetsT cell surface glycoprotein CD3CD22

Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwanAustralia +[10]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesTeneobio Inc

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesJohnson & Johnson (China) Investment Ltd

Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A